USA - engelsk - NLM (National Library of Medicine)

wg critical care, llc - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 5 mg in 1 ml - levofloxacin injection in 5% dextrose is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-suscep

USA - engelsk - NLM (National Library of Medicine)

wg critical care, llc - sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330), ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd) - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus, escherichia coli * , klebsiella spp.* (including k. pneumoniae * ), proteus mirabilis * , bacteroides fragilis * , enterobacter spp.* , and acinetobacter calcoaceticus * . note: for information on use in pediatric patients see precautions, pediatric use and clinical studies sections. intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli, klebsiella spp. (including k. pneumoniae * ), bacteroides spp. (including b. fragilis ), and enterobacter spp.* . gynecological infections caused by beta-lactamase producing strains of escherichia coli * , and bacteroides spp.* (including b. fragilis * ). *efficacy for this organism in this organ system was studied in fewer than 10 infections. whi

USA - engelsk - NLM (National Library of Medicine)

wg critical care, llc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd) - ampicillin 250 mg - ampicillin for injection, usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: respiratory tract infections caused by s. pneumoniae, staphylococcus aureus (penicillinase and non-penicillinase producing), h. influenzae and group a beta-hemolytic streptococci. bacterial meningitis caused by e. coli, group b streptococci, and other gram-negative bacteria (listeria monocytogenes, n. meningitidis ). the addition of an aminoglycoside with ampicillin may increase its effectiveness against gram-negative bacteria. septicemia and endocarditis caused by susceptible gram-positive organisms including streptococcus spp., penicillin-g-susceptible staphylococci and enterococci. gram-negative sepsis caused by e. coli, proteus mirabilis and salmonella spp. responds to ampicillin. endocarditis due to enterococcal strains usually respond to intravenous therapy. the addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. urinary tract infections caused by sensitive strains of e. coli and proteus mirabilis . gastrointestinal infections caused by salmonella typhi (typhoid fever), other salmonella spp. and shigella spp. (dysentery) usually respond to oral or intravenous therapy. bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. therapy may be instituted prior to obtaining results of susceptibility testing. it is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. a change to oral ampicillin may be made as soon as appropriate. indicated surgical procedures should be performed. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, usp and other antibacterial drugs, ampicillin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. a history of a previous hypersensitivity reaction to any of the penicillins is a contraindication.

USA - engelsk - NLM (National Library of Medicine)

wg critical care, llc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd) - ampicillin for injection, usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: respiratory tract infections caused by s. pneumoniae, staphylococcus aureus (penicillinase and non-penicillinase producing), h. influenzae and group a beta-hemolytic streptococci. bacterial meningitis caused by e. coli, group b streptococci, and other gram-negative bacteria (listeria monocytogenes, n. meningitidis ). the addition of an aminoglycoside with ampicillin may increase its effectiveness against gram-negative bacteria. septicemia and endocarditis caused by susceptible gram-positive organisms including streptococcus spp., penicillin-g-susceptible staphylococci and enterococci. gram-negative sepsis caused by e. coli, proteus mirabilis and salmonella spp. responds to ampicillin. endocarditis due to enterococcal strains usually respond to intravenous therapy. the addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. urinary tract infections caused by sensitive strains of e. coli and proteus mirabilis . gastrointestinal infections caused by salmonella typhi (typhoid fever), other salmonella spp. and shigella spp. (dysentery) usually respond to oral or intravenous therapy. bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. therapy may be instituted prior to obtaining results of susceptibility testing. it is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. a change to oral ampicillin may be made as soon as appropriate. indicated surgical procedures should be performed. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, usp and other antibacterial drugs, ampicillin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. a history of a previous hypersensitivity reaction to any of the penicillins is a contraindication.

USA - engelsk - NLM (National Library of Medicine)

wg critical care, llc - nafcillin sodium (unii: 49g3001bck) (nafcillin - unii:4cnz27m7rv) - nafcillin 1 g - nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see clinical pharmacology – susceptibility test methods ). nafcillin should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to methicillin-resistant staphylococcus sp., therapy with nafcillin for injection should be discontinued and alternative therapy provided. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nafcillin for injection and other antibacterial drugs, nafcillin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in s

USA - engelsk - NLM (National Library of Medicine)

wg critical care, llc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin 10 g in 100 ml - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus, escherichia coli,* klebsiella spp.* (including k. pneumoniae* ),proteus mirabilis,* bacteroides fragilis,* enterobacter spp.,* and acinetobacter calcoaceticus.* note: for information on use in pediatric patients see precautions , pediatric use and clinical studies sections. intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli, klebsiella spp. (including k. pneumoniae* ), bacteroides spp. (including b. fragilis ), and enterobacter spp.* gynecological infections caused by beta-lactamase producing strains of escherichia coli,* and bacteroides spp.* (including b. fragilis* ). * efficacy for this organism in this organ system was studied in fewer than 10 infections. while ampicilli

USA - engelsk - NLM (National Library of Medicine)

wg critical care, llc - penicillin g potassium (unii: vl775zth4c) (penicillin g - unii:q42t66vg0c) - penicillin g 1000000 [iu] - therapy: penicillin g potassium for injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g. therapy with penicillin g potassium for injection, usp may be indicated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. clinical indication infecting organism septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis streptococcus pyogenes (group a β-hemolytic streptococcus), other β-hemolytic streptococci including groups c,h,g,l and m, streptococcus pneumoniae and staphylococcus species (non-penicillinase producing strains) anthrax bacillu

USA - engelsk - NLM (National Library of Medicine)

wg critical care, llc - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin 10 g - cefazolin for injection, usp is indicated for the treatment of the following serious infections due to susceptible organisms. respiratory tract infections: due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection, usp is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection, usp in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin‑sensitive and penicillin-resistant), group a beta‑hemolytic streptococci, and other strains of

USA - engelsk - NLM (National Library of Medicine)

wg critical care, llc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin 1 g in 20 ml - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus, escherichia coli * , klebsiella spp.* (including k. pneumoniae * ), proteus mirabilis * , bacteroides fragilis * , enterobacter spp.* , and acinetobacter calcoaceticus * . note: for information on use in pediatric patients see precautions, pediatric use and clinical studies sections. intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli, klebsiella spp. (including k. pneumoniae * ), bacteroides spp. (including b. fragilis ), and enterobacter spp.* . gynecological infections caused by beta-lactamase producing strains of escherichia coli * , and bacteroides spp.* (including b. fragilis * ). *efficacy for this organism in this organ system was studied in fewer than 10 infections. whi

USA - engelsk - NLM (National Library of Medicine)

wg critical care, llc - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin 500 mg - cefazolin for injection, usp is indicated for the treatment of the following serious infections due to susceptible organisms: respiratory tract infections: due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection, usp is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection, usp in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin‑sensitive and penicillin-resistant), group a beta‑hemolytic streptococci, and other strains of